Multiple Sclerosis Research Institute

Recent papers from Multiple Sclerosis Research Institute

1. Predictors of subsequent relapse-independent progression after high-efficacy therapy in relapsing multiple sclerosisFrontiers in Immunology · 2026
2. Automated Text Messages to Link Emergency Department Patients With Public Benefits NavigatorsJAMA Network Open · 2026
3. A Comparative Effectiveness Analysis of Fumarates versus Cladribine in People With MS Transitioning From Anti-CD20 Therapies (P1-20.008)Neurology · 2026
4. Germinoma Presenting With Optic Neuropathy: A Case Report and Literature Review (P5-17.016)Neurology · 2026
5. When psychological signals meet neurological disability: An explainable XGBoost study of dissociative symptoms in people with multiple sclerosisThe Clinical Neuropsychologist · 2026
6. Linkage of Emergency Department Patients With Public Benefits Navigators via Text MessagesJAMA Health Forum · 2026
7. Progressive multifocal leukoencephalopathy in a young adult with DOCK8 deficiency: a case of JC virus reactivation in primary immunodeficiencyJournal of NeuroVirology · 2025
8. Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trialBMJ Neurology Open · 2025
9. Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudyMultiple Sclerosis and Related Disorders · 2025
10. Practical Considerations for Managing Pregnancy in Patients With Multiple SclerosisNeurology Clinical Practice · 2024
11. Mycobacterium haemophilum Related Myelitis in Geographically Linked CasesAnnals of Neurology · 2023
12. The Prevalence of Cancer in Patients with Multiple Sclerosis (MS) who were Under Treatment with Natalizumab (Tysabri): A Systematic Review and Meta-AnalysisInternational Journal of Preventive Medicine · 2023
13. Side Effects That Occurred Early in People With Multiple Sclerosis During the First Year of Treatment With Cladribine Tablets: A Plain Language SummaryNeurodegenerative Disease Management · 2022
14. Policy Evaluation Of The Affordable Care Act Graduate Nurse Education DemonstrationHealth Affairs · 2022
15. Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesNeurology and Therapy · 2021
16. Secondary Progressive Multiple SclerosisNeurology · 2021
17. Effect of Vitamin D Supplements on Relapse Rate and Expanded Disability Status Scale (EDSS) in Multiple Sclerosis (MS): A Systematic Review and Meta-AnalysisInternational Journal of Preventive Medicine · 2021
18. Silent New Brain MRI Lesions in Children with MOG‐Antibody Associated DiseaseAnnals of Neurology · 2020
19. COVID-19 and MS disease-modifying therapiesNeurology Neuroimmunology & Neuroinflammation · 2020
20. Medical Conditions and Crash Risk in Commercial Motor Vehicle DriversJournal of Occupational and Environmental Medicine · 2020